Peter A. Atlman is a notable inventor based in Menlo Park, CA (US). He has made significant contributions to the field of autologous cell therapy, focusing on methods that enhance the efficacy of treatments derived from a patient's own cells. With a total of 2 patents, Atlman's work is paving the way for advancements in personalized medicine.

Latest Patents

Atlman's latest patents include a method for preparing autologous cells and methods of use for therapy. This innovative approach involves expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium, which can be utilized in clinical settings. Additionally, he has developed a business method for performing such expansions as a service for patients in the future. Another significant aspect of his patent is a diagnostic kit for autologous cell therapy, designed to determine whether a patient will respond to the treatment for various diseases. This kit comprises a system for detecting gene and protein expression, utilizing at least two isolated DNA molecules that identify differentially expressed genes in the patient's tissue.

Career Highlights

Peter A. Atlman is currently associated with Biocardia, Inc., where he continues to innovate in the field of cell therapy. His work is instrumental in advancing therapeutic options for patients, particularly those requiring personalized treatment solutions.

Collaborations

Atlman collaborates with notable professionals in his field, including Didier Rouy and Benjamin Koziner. Their combined expertise contributes to the development of cutting-edge therapies and enhances the impact of their innovations.

Conclusion

Peter A. Atlman's contributions to autologous cell therapy represent a significant advancement in medical science. His innovative methods and collaborative efforts are set to improve patient outcomes and redefine treatment paradigms in personalized medicine.